Value of B-type natriuretic peptide for identifying significantly elevated pulmonary artery wedge pressure in patients treated for established chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy
Value of B-type natriuretic peptide for identifying significantly elevated pulmonary artery wedge pressure in patients treated for established chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy
复制标题
DOI：
10.1016/j.amjcard.2004.12.021
复制
发表时间：
2005-04-01
影响因子：
2.8
通讯作者：
Potter, JM
中科院分区：
文献类型：
--
作者：
Parsonage, WA;Galbraith, AJ;Potter, JM
|有人建议，血浆 B 型钠尿肽 (BNP) 水平可用作长期心力衰竭治疗是否充分的无创生物标志物。现代疗法对使用现代市售检测方法测量的 BNP 与心脏充盈压之间关系的影响尚未得到详细研究，因为大多数原始研究早于这些发展。研究人员试图评估 BNP 的诊断准确性，以确定一组接受治疗的严重慢性心力衰竭患者的肺毛细血管楔压 (PCWP) 是否显着升高。 BNP 与 PCWP 相关性良好（r = 0.50，p < 0.001），但该测试识别 PCWP > 15 mm Hg 患者的诊断准确性仅为 74%，很大程度上是因为敏感性较差或存在大量假阴性测试结果。无论血浆 BNP 结果如何，最大限度地进行药物治疗仍然是治疗慢性心力衰竭的最佳方法。 (c) 2005 年，Excerpta Medica Inc.
|It has been suggested that plasma B-type natriuretic peptide (BNP) level may be used as a noninvasive biomarker of the adequacy of long-term heart failure therapy. The effect of contemporary therapy on the relation between BNP measured using modern commercially available assays and cardiac filling pressures has not been studied in detail, because most of the original studies predate these developments. The investigators sought to assess the diagnostic accuracy of BNP to identify significantly elevated pulmonary capillary wedge pressure (PCWP) in a group of patients with severe chronic heart failure on treatment. BNP correlated well with PCWP (r = 0.50, p < 0.001), but the diagnostic accuracy of the test to identify patients with PCWP > 15 mm Hg was only 74%, largely because of poor sensitivity or a large number of false-negative test results. Maximizing medical therapy irrespective of plasma BNP results remains the best approach to managing chronic heart failure. (c) 2005 by Excerpta Medica Inc.